Processa Pharmaceuticals Surges to 279th in Market Rankings with $285 Million Trading Volume

On June 17, 2025, Processa Pharmaceuticals (PCSA) saw a significant surge in trading volume, with a total turnover of $285 million, marking a 3,346.76% increase from the previous day. This substantial rise in trading activity placed Processa at the 279th position in the daily stock market rankings. The stock price of Processa also experienced a notable increase, rising by 18.21%.

Processa Pharmaceuticals has entered into a binding term sheet with Intact Therapeutics, granting Intact the exclusive option to license PCS12852, a 5-HT4 receptor agonist with potential applications in treating gastroparesis and other gastrointestinal motility disorders. Under the terms of the agreement, Processa is eligible to receive a $2.5 million option exercise fee, up to $20 million in development and regulatory milestone payments, and over $432.5 million in commercial milestone payments based on net product sales. Additionally, Intact will pay Processa a double-digit royalty on worldwide net sales of licensed products, excluding South Korea, and provide Processa with a 3.5% equity stake in Intact upon closing.

This strategic partnership is expected to unlock the value of Processa's non-oncology assets while allowing the company to focus on developing next-generation cancer therapies. The collaboration with Intact Therapeutics is seen as a significant step forward in advancing PCS12852 toward commercialization, given Intact's innovative delivery platform and GI-focused strategy. PCS12852 has shown a favorable safety and efficacy profile in clinical studies, making it a promising candidate for patients suffering from gastroparesis and other gastrointestinal disorders.

The exclusive license will become effective upon completion of the definitive agreements and satisfaction of closing conditions, including an amendment of the license agreement between Processa and its licensor. This partnership is anticipated to create value for both companies by providing strategic alignment and shared upside. The collaboration is expected to further enhance Processa's position in the pharmaceutical industry and contribute to the development of innovative treatments for gastrointestinal disorders.